Organogenesis Holdings Inc. (NASDAQ:ORGO) Q4 2022 Earnings Conference Call March 1, 2023 5:00 PM ET

Company Participants

Gary Gillheeney - President and Chief Executive Officer

Dave Francisco - Chief Financial Officer

Conference Call Participants

Ryan Zimmerman - BTIG

Operator

Welcome, ladies and gentlemen to the Fourth Quarter and Fiscal Year 2022 Earnings Conference Call for Organogenesis Holdings Inc. [Operator Instructions] Please note that this conference call is being recorded and that the recording will be available on the company’s website for replay shortly.

Before we begin, I would like to remind everyone that our remarks today may contain forward-looking statements that are based on the current expectations of management and involve inherent risks and uncertainties that could cause actual results to differ materially from those indicated, including the risks and uncertainties described in the company’s filings with the Securities and Exchange Commission, including Item 1A Risk Factors of the company’s most recent annual report and its subsequently filed quarterly reports. You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made.

Although it may voluntarily do so from time to time, the company undertakes no commitment to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. This call will also include references to certain financial measures that are not calculated in accordance with the generally accepted accounting principles or GAAP. We generally refer to these as non-GAAP financial measures. Reconciliations of these non-GAAP financial measures to be the most comparable measures calculated and presented in accordance with GAAP are available in the earnings press release on the Investor Relations portion of our website.

I would now like to turn the call over to Mr. Gary S. Gillheeney, Sr., Organogenesis Holdings’ President and Chief Executive Officer. Please go ahead, sir.

Gary Gillheeney

Thank you, operator, and welcome, everyone, to Organogenesis Holdings fourth quarter and fiscal year 2022 earnings conference call. I am joined on the call today by Dave Francisco, our Chief Financial Officer.

Let me start with a brief agenda of what we’ll cover during our prepared remarks. I will begin with an overview of our fourth quarter revenue results and the update on some of our key operating developments in the recent months. Dave will then provide you with an in-depth review of our fourth quarter financial results, our balance sheet and financial condition at year end and our 2023 financial guidance, which we introduced today with our press release. I will then share a few thoughts on our outlook for 2023 before opening the call up for questions.